SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative platform for discovery of the next generation of breakthrough antibody drugs, today announced another non-exclusive license agreement with a top 20 global pharmaceutical company. This announced agreement follows the announcement in 2010 of the Ablexis pharma consortium, non-exclusive licensing agreements with five of the top 20 global pharmaceutical companies.
